Clinical Trial Update: High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated high-dose furmonertinib in combination with bevacizumab and intrathecal pemetrexed for EGFR-mutated metastatic non-small cell lung can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Metastasis
• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Furmonertinib (furmonertinib)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non-small Cell Lung Cancer Metastatic | Phase 2 | Status: COMPLETED